BELLUS Health：BELLUS Health Inc(BHN0.BE) 走勢圖
BELLUS Health Inc(BHN0.BE) 走勢圖
2023年6月29日—BELLUSHealthInc·成交13.50·開盤13.50·最高13.50·最低13.20·一年內最高13.80·買進-·EPS(TTM)-·PERatio(TTM).- ...。其他文章還包含有：「BELLUSHealthInc(BLU)財報分析和股票健診」、「BELLUSHealthInc(BHN0.DU)走勢圖」、「BELLUSHealthInc.」、「BELLUSHealthInc.(BLU)走勢圖」、「BELLUSHealth」、「OurCompany」、「Pipeline」、「PressReleases」、「《併購》葛蘭素以20億美元收購BellusHealth取得camlipix...
查看更多 離開網站
BELLUS Health Inc (BLU) 財報分析和股票健診
https://statementdog.com
BELLUS Health Inc (BLU) 股價和財報分析，，現金股利殖利率0.0%。最關鍵的指標和圖表，幫助投資人瞭解BLU 股票，判斷值不值得投資。
BELLUS Health Inc(BHN0.DU) 走勢圖
https://tw.stock.yahoo.com
BELLUS Health Inc · 成交13.10 · 開盤13.10 · 最高13.10 · 最低13.10 · 一年內最高13.50 · 買進- · EPS (TTM)- · PE Ratio(TTM). - ...
BELLUS Health Inc.
https://www.moneydj.com
BELLUS Health Inc.(BLU.US)成立於1993年，總部位於加拿大拉瓦爾，為一家臨床階段的生物製藥公司，開發創新療法，其先導候選藥物包含BLU-5937，用於慢性咳嗽的P2X3受體 ...
BELLUS Health Inc.(BLU) 走勢圖
https://tw.stock.yahoo.com
BELLUS Health Inc. · 成交14.74 · 開盤14.74 · 最高14.75 · 最低14.74 · 一年內最高14.76 · 買進- · EPS (TTM)-0.73 · PE Ratio(TTM). - ...
BELLUS Health
https://bellushealth.com
BELLUS HEALTH IS A DRUG DEVELOPMENT COMPANY AND OUR PRODUCT CANDIDATES ARE NOT YET COMMERCIALIZED. INVESTING IN OUR COMMON SHARES INVOLVES A SIGNIFICANT AMOUNT ...
Our Company
https://bellushealth.com
BELLUS HEALTH IS A DRUG DEVELOPMENT COMPANY AND OUR PRODUCT CANDIDATES ARE NOT YET COMMERCIALIZED. INVESTING IN OUR COMMON SHARES INVOLVES A SIGNIFICANT AMOUNT ...
Pipeline
https://bellushealth.com
BELLUS Health is developing camlipixant (BLU-5937), an investigational P2X3 antagonist, for the treatment of refractory chronic cough.
Press Releases
https://ir.bellushealth.com
BELLUS HEALTH IS A DRUG DEVELOPMENT COMPANY AND OUR PRODUCT CANDIDATES ARE NOT YET COMMERCIALIZED. INVESTING IN OUR COMMON SHARES INVOLVES A SIGNIFICANT AMOUNT ...
《併購》 葛蘭素以20億美元收購Bellus Health取得camlipixant
http://www.genetinfo.com
葛蘭素史克斥資20億美元收購Bellus Health取得用於治療難治性慢性咳嗽(RCC)的關鍵候選新藥camlipixant，公司已同意向Bellus 支付每股14.75 美元，比該 ...